Therapeutic Strategies for the Management of HCV/HIV co- infection

HCV/HIV 合并感染的治疗策略

• 批准号: 8745291
• 负责人: Anthony S. Fauci
• 金额: $ 67.21万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8745291
• 关键词: Characteristics; Clinical Treatment; Clinical Trials; Complex; Future; Genotype; HIV; HIV-1; Hepatitis C virus; Immune response; Individual; Infection; Interferons; Liver Fibrosis; Monitor; Patients; Ribavirin; Therapeutic; Viral; base; mortality; novel; novel therapeutics; response

Recent advances in the treatment and monitoring of HIV-1 infection have substantially diminished HIV-associated illness and mortality; however the management of HIV-infected patients has become increasingly complex. We are conducting studies that: (1) evaluate novel therapeutic strategies in the management of hepatitis C virus (HCV)-infected individuals, and (2) identify the signature host response characteristics that predict HCV response to existing treatment and aid in developing better future therapies. This past year, we were able to (1) conduct a novel clinical trial to use interferon free therapy for treatment of HCV genotype 1 infection (2) initiate an interferon and ribavirin free clinical trial for the treatment of HCV in HIV/HCV infected subjects (3) initiate a clinical trial to determine the factors that contribute to HCV clearance using Interferon and ribavirin free therapy.

最近在治疗和监测HIV-1感染方面取得的进展大大减少了与艾滋病毒有关的疾病和死亡率;然而，艾滋病毒感染患者的管理变得越来越复杂。我们正在进行以下研究：（1）评估丙型肝炎病毒（HCV）感染者管理的新治疗策略，（2）确定预测HCV对现有治疗反应的标志性宿主反应特征，并帮助开发更好的未来疗法。在过去的一年里，我们能够（1）进行一项新的临床试验，使用干扰素治疗HCV基因型1感染（2）启动一项干扰素和利巴韦林免费临床试验，用于治疗HIV/HCV感染受试者的HCV（3）启动一项临床试验，以确定使用干扰素和利巴韦林免费治疗HCV清除的因素。